Klaria Pharma Holding AB (publ.) (KLAR.ST)
SEK 1.17
(-4.12%)
SEK 1.17
(-4.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -14.77 Million SEK | 67.24% |
| 2022 | -44.78 Million SEK | 35.98% |
| 2021 | -39.41 Million SEK | -97.51% |
| 2020 | -35.41 Million SEK | -220.44% |
| 2019 | -11.05 Million SEK | 37.65% |
| 2018 | -17.72 Million SEK | -47.95% |
| 2017 | -11.98 Million SEK | 17.2% |
| 2016 | -14.54 Million SEK | -158.74% |
| 2015 | -1000.00 SEK | -828.69% |
| 2014 | -602.14 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.97 Million SEK | 29.44% |
| 2024 Q1 | -2.81 Million SEK | -130.8% |
| 2023 Q2 | -6.77 Million SEK | -324.58% |
| 2023 Q3 | -6.87 Million SEK | -1.52% |
| 2023 FY | - SEK | 66.76% |
| 2023 Q4 | -6.93 Million SEK | -0.9% |
| 2023 Q1 | -1.59 Million SEK | 74.94% |
| 2022 Q2 | -10.64 Million SEK | 35.07% |
| 2022 Q1 | -16.38 Million SEK | 55.33% |
| 2022 Q4 | -6.36 Million SEK | 44.11% |
| 2022 FY | - SEK | 35.98% |
| 2022 Q3 | -11.38 Million SEK | -7.04% |
| 2021 Q3 | -11.8 Million SEK | -5.55% |
| 2021 Q2 | -11.18 Million SEK | -155.22% |
| 2021 Q4 | -36.67 Million SEK | -210.76% |
| 2021 FY | - SEK | -97.51% |
| 2021 Q1 | 20.25 Million SEK | 253.13% |
| 2020 Q3 | -9.29 Million SEK | -54.87% |
| 2020 FY | - SEK | -220.44% |
| 2020 Q4 | -13.22 Million SEK | -42.29% |
| 2020 Q2 | -6 Million SEK | 12.98% |
| 2020 Q1 | -6.89 Million SEK | -307.08% |
| 2019 Q3 | -4.47 Million SEK | 13.99% |
| 2019 Q2 | -5.19 Million SEK | -1771.38% |
| 2019 Q1 | 311 Thousand SEK | 105.47% |
| 2019 FY | - SEK | 37.65% |
| 2019 Q4 | -1.69 Million SEK | 62.11% |
| 2018 Q1 | -3.83 Million SEK | 1.72% |
| 2018 FY | - SEK | -47.95% |
| 2018 Q3 | -3.71 Million SEK | 17.12% |
| 2018 Q2 | -4.48 Million SEK | -16.86% |
| 2018 Q4 | -5.68 Million SEK | -52.95% |
| 2017 Q2 | -3.45 Million SEK | -8.89% |
| 2017 Q4 | -3.9 Million SEK | -170.24% |
| 2017 Q3 | -1.44 Million SEK | 58.15% |
| 2017 FY | - SEK | 17.2% |
| 2017 Q1 | -3.17 Million SEK | -4.93% |
| 2016 Q3 | -3.16 Million SEK | 28.85% |
| 2016 FY | - SEK | -158.74% |
| 2016 Q4 | -3.02 Million SEK | 4.55% |
| 2016 Q1 | -3.84 Million SEK | -5.0% |
| 2016 Q2 | -4.45 Million SEK | -15.89% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q2 | -467 Thousand SEK | 0.0% |
| 2015 Q3 | -1.5 Million SEK | -222.91% |
| 2015 Q4 | -3.65 Million SEK | -142.51% |
| 2015 FY | - SEK | -828.69% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -7.881% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | 60.996% |
| BioGaia AB (publ) | 466.19 Million SEK | 103.168% |
| Enzymatica AB (publ) | -41.12 Million SEK | 64.082% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 65.693% |
| Gabather AB (publ) | 37 Thousand SEK | 40018.919% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | 45.214% |
| Nanexa AB (publ) | -70.79 Million SEK | 79.136% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | -19.692% |
| ODI Pharma AB | 1.36 Million SEK | 1180.181% |
| Orexo AB (publ) | -22 Million SEK | 32.864% |
| Probi AB (publ) | 115.61 Million SEK | 112.775% |
| Swedencare AB (publ) | 484 Million SEK | 103.052% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 100.204% |
| Toleranzia AB | -7.39 Million SEK | -99.649% |
| Vivesto AB | -89.75 Million SEK | 83.545% |